• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Granules India Ltd.
    22 Aug 2025
    543.40
    0.05%
    Can Granules India leverage its strong product pipeline to offset recent profit declines?
    Can Granules India leverage its strong product pipeline to offset recent profit declines?
    Economic Times
    Granules India's stock shows a slight recovery despite reporting lower profits in the June quarter. Investors are positive about the company's product pipeline and business stabilisation. The company anticipates better growth in FY27. Approvals for six products in Europe are awaited. Granules focuses on CNS, ADHD, and oncology products. The Gagillapur facility remediation is progressing well with US FDA.
    Copy LinkShare onShare on Share on Share on
    Granules India Ltd. is trading above all available SMAs
    logo
    Concord Biotech Ltd.
    21 Aug 2025, 03:05PM
    1695.10
    2.26%
    Concord Biotech shares jump 6 per cent; here's what is fueling the gains
    Business Standard
    The upward movement in the pharmaceutical company's stock price followed an announcement regarding the company's Limbasi API facility
    Copy LinkShare onShare on Share on Share on
    Concord Biotech Ltd.'s price crossed above 30Day SMA today
    logo
    Sai Life Science Ltd.
    20 Aug 2025, 07:06PM
    913.65
    2.12%
    Sai Life Sciences secures SBTi validation for near-term climate targets
    Business Line
    Sai Life Sciences has committed to reduce absolute scope 1 and 2 GHG emissions 58.8% by FY35 with FY24 as base year
    Copy LinkShare onShare on Share on Share on
    Sai Life Science Ltd. has gained 26.52% in the last 6 Months
    logo
    Aurobindo Pharma Ltd.
    20 Aug 2025, 02:26PM
    1119.20
    -0.86%
    Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva
    Business Standard
    Shortly after reports of the potential acquisition surfaced, Aurobindo clarified that no binding agreement or definitive decision has been made regarding the deal
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1126.0
    logo
    Natco Pharma Ltd.
    20 Aug 2025, 12:17PM
    US FDA Classification
    884.25
    -0.01%
    Natco Pharma introduces generic Bosentan in US for pulmonary arterial hypertension treatment
    Business Line
    Natco received USFDA approval for its ANDA and secured the coveted first-to-file status, granting it 180-day generic drug exclusivity
    Copy LinkShare onShare on Share on Share on
    Natco Pharma Ltd. is trading below its 50 day SMA of 915.8
    logo
    Glenmark Pharmaceuticals Ltd.
    19 Aug 2025
    2085.20
    -1.10%
    'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results Check Target Price
    'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results Check Target Price
    NDTV Profit
    Motilal Oswal maintain 'Buy' rating on Glenmark Pharma and hikes target price sees strategic transformation to be underway
    Copy LinkShare onShare on Share on Share on
    Glenmark Pharmaceuticals Ltd. is trading above all available SMAs
    Glenmark Pharma Eyes 19-20% Ebitda Margin In FY26 Driven By Strong Performance Across Markets
    NDTV Profit | 19 Aug 2025 1 more
    Glenmark Pharma falls 5% in 2 days on Q1 show; Here's what analysts suggest
    Business Standard | 19 Aug 2025
    logo
    Alembic Pharmaceuticals Ltd.
    19 Aug 2025
    959.00
    0.17%
    Alembic Pharma shares rise 2% on pulmonary hypertension drug approval
    Business Standard
    Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr
    logo
    Marksans Pharma Ltd.
    18 Aug 2025
    179.11
    0.41%
    Marksans Pharma gains 3% on UK MHRA approval for subsidiary; details here
    Business Standard
    The upward movement in Marksans Pharma's share price came after the company announced that its wholly owned subsidiary, Relonchem in the UK, had received marketing authorisation for its products
    Copy LinkShare onShare on Share on Share on
    Marksans Pharma Ltd. has lost -43.74% in the last 1 Year
    logo
    Alembic Ltd.
    18 Aug 2025
    106.53
    0.04%
    Alembic gets USFDA nod for generic drug for skin condition
    Business Line
    The company has received final approval from the US Food & Drug Administration for its abbreviated new drug application for Tretinoin Cream USP, the drug maker said in a statement
    Copy LinkShare onShare on Share on Share on
    Alembic Ltd. is trading below its 50 day SMA of 109.6
    logo
    Alembic Pharmaceuticals Ltd.
    18 Aug 2025
    959.00
    0.17%
    Alembic gets USFDA's approval for generic acne drug Tretinoin Cream
    Business Standard
    Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication to treat acne vulgaris in the US market. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP (0.025 per cent), the drug maker said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025 pr cent, of Bausch Health US, LLC, it added. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. According to IQVIA, Tretinoin cream USP, 0.025 per cent, has an estimated market size of USD 94 million for the twelve months ending June 2025. Shares of the company were trading 1.03 per cent up at Rs 968.10 apiece on BSE.
    Copy LinkShare onShare on Share on Share on
    Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 949.1
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd